Supriya Lifescience Limited — Results, 03-02-2026: Reply to Clarification- Financial results

The company clarified that the absence of segment details was a typographical error; it operates in a single Pharmaceuticals segment. A delay in submitting results from a recent board meeting was due to internal technical issues, now resolved. This does not impact previously disclosed financial figures.